Peroxisome proliferator-activated receptors in macrophage biology: friend or foe?

被引：51

作者：

Moore, KJ ^{[1
]}

Fitzgerald, ML ^{[1
]}

Freeman, MW ^{[1
]}

机构：

[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lipid Metab Unit, Boston, MA 02114 USA

来源：

CURRENT OPINION IN LIPIDOLOGY | 2001年 / 12卷 / 05期

关键词：

D O I：

10.1097/00041433-200110000-00007

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Peroxisome proliferator-activated receptor (PPAR)-gamma is a nuclear hormone receptor, with a well-established role in adipogenesis and glucose metabolism. Over the past 3 years several laboratories have reported that this protein can influence macrophage responses to a variety of inflammatory stimuli. The effect of PPAR-gamma activation on macrophage lipid uptake, cholesterol efflux, and cytokine production have all recently been examined in several in-vitro culture systems. In addition, PPAR-gamma ligands have been shown to influence atherosclerotic lesion formation in murine models of that disease. This review attempts to summarize and critically evaluate that work and its implications for the use of PPAR-gamma activators in understanding and treating the pathogenetic processes that contribute to atherosclerotic plaque formation. Curr Opin Lipidol 12:519-527,, (C) 2001 Lippincott Williams & Wilkins.

引用

页码：519 / 527

页数：9

共 45 条

[1] Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells [J].

Bamba, H ;

Ota, S ;

Kato, A ;

Kawamoto, C ;

Fujiwara, K .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 273 (02) :485-491

[2] A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis [J].

Chawla, A ;

Boisvert, WA ;

Lee, CH ;

Laffitte, BA ;

Barak, Y ;

Joseph, SB ;

Liao, D ;

Nagy, L ;

Edwards, PA ;

Curtiss, LK ;

Evans, RM ;

Tontonoz, P .

MOLECULAR CELL, 2001, 7 (01) :161-171

[3] PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation [J].

Chawla, A ;

Barak, Y ;

Nagy, L ;

Liao, D ;

Tontonoz, P ;

Evans, RM .

NATURE MEDICINE, 2001, 7 (01) :48-52

[4] Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice - Pleiotropic effects on CD36 expression and HDL [J].

Chen, Z ;

Ishibashi, S ;

Perrey, S ;

Osuga, J ;

Gotoda, T ;

Kitamine, T ;

Tamura, Y ;

Okazaki, H ;

Yahagi, N ;

Iizuka, Y ;

Shionoiri, F ;

Ohashi, K ;

Harada, K ;

Shimano, H ;

Nagai, R ;

Yamada, N .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (03) :372-377

[5] PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway [J].

Chinetti, G ;

Lestavel, S ;

Bocher, V ;

Remaley, AT ;

Neve, B ;

Torra, IP ;

Teissier, E ;

Minnich, A ;

Jaye, M ;

Duverger, N ;

Brewer, HB ;

Fruchart, JC ;

Clavey, V ;

Staels, B .

NATURE MEDICINE, 2001, 7 (01) :53-58

[6] Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice [J].

Collins, AR ;

Meehan, WP ;

Kintscher, U ;

Jackson, S ;

Wakino, S ;

Noh, G ;

Palinski, W ;

Hsueh, WA ;

Law, RE .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (03) :365-371

[7] Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor γ ligands and agonists [J].

Davies, SS ;

Pontsler, AV ;

Marathe, GK ;

Harrison, KA ;

Murphy, RC ;

Hinshaw, JC ;

Prestwich, GD ;

St Hilaire, A ;

Prescott, SM ;

Zimmerman, GA ;

McIntyre, TM .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (19) :16015-16023

[8] Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor γ (BPARγ) heterodimer:: A basis for new therapeutic strategies [J].

Desreumaux, P ;

Dubuquoy, L ;

Nutten, S ;

Peuchmaur, M ;

Englaro, W ;

Schoonjans, K ;

Derijard, B ;

Desvergne, B ;

Wahli, W ;

Chambon, P ;

Leibowitz, MD ;

Colombel, JF ;

Auwerx, J .

JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (07) :827-838

[9]

Dubuquoy L, 2000, GASTROEN CLIN BIOL, V24, P719

[10] Cardiac and glycemic benefits of troglitazone treatment in NIDDM [J].

Ghazzi, MN ;

Perez, JE ;

Autonucci, TK ;

Driscoll, JH ;

Huang, SM ;

Faja, BW ;

Whitcomb, RW .

DIABETES, 1997, 46 (03) :433-439

← 1 2 3 4 5 →